MBX · MBX Biosciences, Inc. Common Stock

MBX Biosciences reported its first quarter 2026 financial results, highlighting a net loss of $23.5 million, slightly improved from $23.9 million in the same period last year. The reduction in net loss was driven by higher interest and other income ($3.7 million vs. $2.6 million), partially offset by increased operating expenses. Research and development expenses decreased to $18.5 million from $22.4 million, primarily due to higher costs for the canvuparatide Phase 2 trial and preclinical activities for MBX 4291 in the prior year. General and administrative expenses rose to $8.8 million from $4.1 million, reflecting increased personnel costs and separation-related expenses as the company expands its infrastructure. The company ended the quarter with $440.0 million in cash, cash equivalents, and marketable securities, providing a runway into 2029. Key operational highlights include the acceptance of Phase 2 results for once-weekly canvuparatide for oral presentation at ENDO 2026 in June, and the on-track initiation of a Phase 3 trial in Q3 2026. The appointment of Mark Soued as Chief Commercial Officer strengthens the leadership team for future commercialization. Additionally, the company plans to host an Obesity Day on May 11, 2026, to present initial blinded data from the MBX 4291 Phase 1 trial and update on its expanding obesity pipeline. The company also expects to nominate an amycretin prodrug candidate in Q2 2026 and a GLP-1/GIP/GCGR triple-agonist prodrug in Q3 2026. Overall, the quarter reflects disciplined spending and strong cash position, with significant upcoming catalysts in the pipeline.